EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database

Katarina Đogatović iD, Katarina Vučićević iD, Milena Kovačević iD, Milica Ćulafić, Branislava Miljković iD, Sandra Vezmar Kovačević

Journal of Clinical Medicine · 12.03.2026 · 15 (6) · 2172

DOI: 10.3390/jcm15062172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.03.2026. Verfasst von Katarina Đogatović und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Drug repurposing represents a promising strategy to expand therapeutic options for inflammatory bowel disease (IBD), a chronic condition with persistent unmet clinical needs. This study aimed to identify existing drugs with potential relevance for IBD by exploring inverse associations in the FDA Adverse Event Reporting System (FAERS) as a hypothesis-generating, real-world data approach.

Methods

In this retrospective observational pharmacovigilance study, drug–IBD associations were extracted from the FAERS database using OpenVigil 2.1. Inverse associations were identified based on reporting odds ratios (ROR) < 1 with adjusted p-values < 0.05. Identified drug–event pairs were further evaluated for pharmacokinetic feasibility, clinical applicability, and biological plausibility in the context of IBD, with the exclusion of drugs with implausible indications, contraindications, or mechanisms inconsistent with IBD pathophysiology. Given the immune-mediated nature of IBD and the breadth of the identified candidates, detailed evaluation focused on immunomodulatory agents.

Results

Among the 3585 initial drug–IBD combinations, 73 candidates met the predefined criteria for statistical significance and feasibility. From these, nine drugs were prioritized based on inverse signal strength and mechanistic relevance to immune modulation pathways implicated in IBD. The strongest inverse association with IBD was observed for lenalidomide (ROR 0.056, 95% CI 0.043–0.073), followed by dupilumab (ROR 0.213, 95% CI 0.185–0.245), cyclophosphamide (ROR 0.215, 95% CI 0.175–0.265), fingolimod (ROR 0.216, 95% CI 0.205–0.334), dimethyl fumarate (ROR 0.332, 95% CI 0.275–0.400), apremilast (ROR 0.357, 95% CI 0.296–0.431), imatinib (ROR 0.423, 95% CI 0.339–0.527), glatiramer acetate (ROR 0.446, 95% CI 0.352–0.565), and interferon beta-1a (ROR 0.594, 95% CI 0.533–0.662). These agents possess immunomodulatory properties relevant to inflammatory pathways implicated in IBD; however, clinical evidence supporting the therapeutic efficacy of some candidates remains variable or incomplete.

Conclusions

By integrating inverse signal detection with clinical and biological assessment, this study demonstrates how pharmacovigilance data can be extended from traditional safety surveillance toward systematic drug repurposing applications. The findings generate testable hypotheses and highlight candidate therapies that warrant further experimental and clinical investigation in IBD.

Schlagwörter

Stichwörter der Autor:innen

data miningdrug repurposingpharmacovigilancesignal detection

Autor:innen und Institutionen

  • Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.

ORCID-Profile: Katarina Đogatović, Katarina Vučićević, Milena Kovačević, Branislava Miljković

Förderung

  • Science Fund of the Republic of Serbia

Zitieren

APA

Đogatović, K., Vučićević, K., Kovačević, M., Ćulafić, M., Miljković, B., & Kovačević, S. V. (2026). Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database. Journal of Clinical Medicine, 15(6), 2172. https://doi.org/10.3390/jcm15062172

Vancouver

Đogatović K, Vučićević K, Kovačević M, Ćulafić M, Miljković B, Kovačević SV. Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database. Journal of Clinical Medicine. 2026;15(6):2172. doi:10.3390/jcm15062172

BibTeX
@article{ogatovi2026,
  author = {Đogatović, Katarina and Vučićević, Katarina and Kovačević, Milena and Ćulafić, Milica and Miljković, Branislava and Kovačević, Sandra Vezmar},
  title = {Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {6},
  pages = {2172},
  doi = {10.3390/jcm15062172}
}
Kostenlos starten →